MoonLake Immunotherapeutics

Yahoo Finance • 3 months ago

Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now?

We recently compiled a list of the 10 Best Guru Stocks To Buy Now. In this article, we will have a look at where MoonLake Immunotherapeutics (NASDAQ:MLTX) ranks among the best guru stocks to buy now. Due to the plethora of investment opti... Full story

Yahoo Finance • 3 months ago

MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock

We recently compiled a list of the 10 Worst ADR Stocks To Buy According to Short Sellers.In this article, we are going to take a look at where MoonLake Immunotherapeutics (NASDAQ:MLTX) stands against the other ADR stocks. An American Depo... Full story

Yahoo Finance • last year

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Announced positive full 24-week data from the global Phase 2 MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly p... Full story

Yahoo Finance • last year

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis First placebo-controlled randomized trial in active psoriatic arthritis (PsA) using a Nanobody® to report positive topl... Full story

Yahoo Finance • last year

12 Best Performing NASDAQ Stocks in 2023

In this piece, we will take a look at the 12 best performing NASDAQ stocks in 2023. If you want to skip our introduction to the NASDAQ's performance this year and the broader stock market, then read 5 Best Performing NASDAQ Stocks in 2023.... Full story

Yahoo Finance • last year

15 Best Performing Stocks in the Last 3 Months

In this article, we discuss 15 best performing stocks in the last 3 months. If you want to skip our detailed discussion about the stock market performance, head directly to 5 Best Performing Stocks in the Last 3 Months. Despite a multitud... Full story

Yahoo Finance • last year

MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares

MoonLake ImmunotherapeuticsAnnounces Pricing of$40 Million Upsized Public Offering of Class A Ordinary Shares ZUG, Switzerland, June 28, 2023 – MoonLake Immunotherapeutics (Nasdaq:MLTX) (“MoonLake”), a clinical-stage biotechnology compan... Full story

Yahoo Finance • last year

MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering

MoonLake ImmunotherapeuticsAnnouncesProposed Underwritten Public Offering ZUG, Switzerland, June 26, 2023 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level th... Full story

Yahoo Finance • 2 years ago

MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update Capital Markets Day held in April highlighted the differentiating features of sonelokimab and strong competitive position following co... Full story